Future studies on the involvement of VIMP in CRC should investigate the underlying mechanisms by which VIMP affects PFA and cholesterol-to-total-lipids ratio in IDL, enabling the identification of potential therapeutic targets for CRC treatment. This evidence concerns the gene SELENOS and colorectal carcinoma.